OHSU’s Knight Cancer Institute has recruited Charles D. Blanke, M.D., chair-elect of SWOG, one of the largest National Cancer Institute-funded clinical trial networks. As leader of SWOG, Dr. Blanke will oversee $40 million in research funding annually. The Knight Cancer Institute is expected to benefit by receiving $20 to $25 million and increased access to SWOG clinical trials.
Dr. Blanke’s recruitment supports the Knight Cancer Institute’s mission of being a leader in personalized cancer medicine. Dr. Blanke said: “I was drawn to the Knight Cancer Institute because of its leadership in molecularly-driven, personalized cancer medicine, as well as its willingness to make significant investments in research to advance that field. The work Knight investigators are doing to pave the way for development of more targeted therapies aimed at curing a variety of cancers based on the specific biology of a patient’s tumor, is a major focus of SWOG research as well.”
Dr. Blanke is currently vice-president of systemic therapy for the British Columbia Cancer Agency, chief of medical oncology at the University of British Columbia and chair of the Gastrointestinal Stromal Tumor Task Force for the NCI’s Gastrointestinal Steering Committee. He will join OHSU in February 2013.
Read the full OHSU News release for more information.